Wave life sciences announces initiation of dosing in phase 2 forward-53 trial of wve-n531 in duchenne muscular dystrophy

Forward-53 is fully enrolled with potentially registrational dystrophin expression data expected in 2024 previous clinical proof-of-concept data demonstrated highest level of exon skipping ever observed in the clinic and that wve-n531 was present in myogenic stem cells, which are important for potential muscle regeneration cambridge, mass., dec. 15, 2023 (globe newswire) -- wave life sciences ltd.
WVE Ratings Summary
WVE Quant Ranking